%A 周丽娜，李红梅 %T Adverse reactions and symptomatic treatment of immunological checkpoint inhibitors in tumor therapy %0 Journal Article %D 2017 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673-422X.2017.11.014 %P 860-863 %V 44 %N 11 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_10352.shtml} %8 2017-11-08 %X Immunological checkpoint inhibitors include monoclonal antibodies of cytotoxic T lymphocyte antigen4 (CTLA4) and programmed cell death1 (PD1). AntiCTLA4 drug ezetimab (ipilimumab) and antiPD1 drug (pembrolizumab and nivolumab) are approved for the treatment of melanoma and nonsmall cell lung cancer. The effects of these drugs on renal cell carcinoma, bladder cancer, breast cancer, gastrointestinal cancer and other types of cancers are still in largescale clinical trials. These drugs have good effects in the clinical application, but they inevitably lead to many adverse reactions.